Clinical features present at T1 | Model 1: remissiona at T2 (N = 48) | Model 2: extended remissiona (N = 31) | Model 3: durable remissiona (N = 13) | ||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | P value | OR | 95% CI | P value | OR | 95% CI | P value | |
Increased CKb | - | - | - | 3.18 | 1.17–8.67 | .024* | - | - | - |
Facial erythemab | - | - | - | - | - | - | 0.11 | 0.01–0.81 | .030* |
Digital ulcersb | - | - | - | 0.25 | 0.08–0.77 | .015* | - | - | - |
Trombocytopheniab, c | 0.05 | 0.01–-0.44 | .006** | - | - | - | - | - | - |
FVC % pred (pr 10%) | 1.37 | 1.04–1.79 | .026* | 1.56 | 1.13–2.16 | .007** | 1.71 | 1.04–2.80 | .033* |
NSAID medication | - | - | - | - | - | - | 0.05 | 0.00–0.73 | .028* |
Negative anti-RNP | - | - | - | - | - | - | 15.0 | 1.97–113.59 | .009** |